Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

Inclusion Criteria: * Patient who understands and speaks one of the country official languages and signed Informed Consent Form * Histologically proven relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL) of the following histology at relapse: diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), follicular lymphoma Grade 3B per World Health Organization (WHO) 2016 classification and Primary mediastinal Bcell lymphomas. Indolent B-NHL who transformed into aggressive B-NHL and were previously treated with Rituximab-Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP) are eligible. * Tumoral tissue (at diagnosis or relapse) available for central pathology review, exploratory endpoints and ancillary studies * Positron-emission tomography (PET)-positive disease * Patients must have received adequate first-line therapy including at a minimum: an anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (CHOP) or CHOP-like chemotherapy * Relapsed or refractory disease after first-line chemoimmunotherapy (full dose of R-CHOP or R-CHOP-like regimen), documented by PET-scan * At least 2 weeks must have elapsed since any prior systemic cancer therapy at the time the patient provides consent * Patients must be autologous stem cell transplantation (ASCT)-ineligible * Patients must be CAR-T-eligible * Females of childbearing potential must have a negative serum or urine…